Abstract:Cancer stem cells (CSCs) found within cancer tissue play a pivotal role in its resistance to therapy and its potential to metastasize, contributing to elevated mortality rates among patients. Significant strides in understanding the molecular foundations of CSCs have led to preclinical investigations and clinical trials focused on CSC regulator β-catenin signaling targeted interventions in malignancies. As part of the ongoing advancements in marine-organism-derived compound development, it was observed that among the six analogs of Renieramycin T (RT), a potential lead alkaloid from the blue sponge Xestospongia sp., the compound DH_32, displayed the most robust anti-cancer activity in lung cancer A549, H23, and H292 cells. In various lung cancer cell lines, DH_32 exhibited the highest efficacy, with IC50 values of 4.06 ± 0.24 μM, 2.07 ± 0.11 μM, and 1.46 ± 0.06 μM in A549, H23, and H292 cells, respectively. In contrast, parental RT compounds had IC50 values of 5.76 ± 0.23 μM, 2.93 ± 0.07 μM, and 1.52 ± 0.05 μM in the same order. Furthermore, at a dosage of 25 nM, DH_32 showed a stronger ability to inhibit colony formation compared to the lead compound, RT. DH_32 was capable of inducing apoptosis in lung cancer cells, as demonstrated by increased PARP cleavage and reduced levels of the proapoptotic protein Bcl2. Our discovery confirms that DH_32 treatment of lung cancer cells led to a reduced level of CD133, which is associated with the suppression of stem-cell-related transcription factors like OCT4. Moreover, DH_32 significantly suppressed the ability of tumor spheroids to form compared to the original RT compound. Additionally, DH_32 inhibited CSCs by promoting the degradation of β-catenin through ubiquitin–proteasomal pathways. In computational molecular docking, a high-affinity interaction was observed between DH_32 (grid score = −35.559 kcal/mol) and β-catenin, indicating a stronger binding interaction compared to the reference compound R9Q (grid score = −29.044 kcal/mol). In summary, DH_32, a newly developed derivative of the right-half analog of RT, effectively inhibited the initiation of lung cancer spheroids and the self-renewal of lung cancer cells through the upstream process of β-catenin ubiquitin–proteasomal degradation.

Riccardin D-26, a Synthesized Macrocyclic Bisbibenzyl Compound, Inhibits Human Oral Squamous Carcinoma Cells KB and KB/VCR: in Vitro and in Vivo Studies.

Riccardin D-26, a Synthesized Macrocyclic Bisbibenzyl Compound, Inhibits Human Hepatocellular Carcinoma Growth Through Induction of Apoptosis in P53-Dependent Way

Novel Synthetic Derivative of Renieramycin T Right-Half Analog Induces Apoptosis and Inhibits Cancer Stem Cells via Targeting the Akt Signal in Lung Cancer Cells.

Simplified Synthesis of Renieramycin T Derivatives to Target Cancer Stem Cells Via Β-Catenin Proteasomal Degradation in Human Lung Cancer

Riccardin D-N Induces Lysosomal Membrane Permeabilization by Inhibiting Acid Sphingomyelinase and Interfering with Sphingomyelin Metabolism in Vivo.

Bruceine D Induces Apoptosis in Human Non-Small Cell Lung Cancer Cells Through Regulating JNK Pathway

Enzymes responsible for the metabolism of saikosaponins from Eubacterium sp. A-44, a human intestinal anaerobe.

Design, Synthesis and Biological Evaluation of Nitrogen-Containing Macrocyclic Bisbibenzyl Derivatives As Potent Anticancer Agents by Targeting the Lysosome.

In vitro and in vivo evaluation of riccardin D nanosuspensions with different particle size.

A Novel Multikinase Inhibitor R8 Exhibits Potent Inhibition on Cancer Cells Through Both Apoptosis and Autophagic Cell Death

Anti-tumor effect of carrimycin on oral squamous cell carcinoma cells in vitro and in vivo

Β,β-Dimethylacrylshikonin Induces Mitochondria Dependent Apoptosis Through ERK Pathway in Human Gastric Cancer SGC-7901 Cells.

Marchantin C, a Macrocyclic Bisbibenzyl, Induces Apoptosis of Human Glioma A172 Cells.

Antiproliferation- and Apoptosis-Inducible Effects of a Novel Nitrated [6,6,6]Tricycle Derivative (SK2) on Oral Cancer Cells

In Vitro Anticancer Screening and Preliminary Mechanistic Study of A-Ring Substituted Anthraquinone Derivatives

Anti-tumor activity and immunogenicity of a succinoglycan riclin

DHPAC, a Novel Synthetic Microtubule Destabilizing Agent, Possess High Anti-Tumor Activity in Vincristine-Resistant Oral Epidermoid Carcinoma in Vitro and in Vivo

A Novel Potent CDK4/6 Inhibitor BPI-16350 in Preclinical Cancer Models

Design, Synthesis, Biological Evaluation and Molecular Modeling Study of Novel Macrocyclic Bisbibenzyl Analogues As Antitubulin Agents

Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.

A milbemycin compound isolated from Streptomyces Sp. FJS31-2 with cytotoxicity and reversal of cisplatin resistance activity in A549/DDP cells